Human Anti-Epstein Barr virus IgG ELISA Kit (EBV-VCA) is an indirect ELISA for the qualitative detection of IgG class antibodies against Epstein Barr virus (EBV-VCA) in human plasma and serum samples.
- Colorimetric readout - 450 nm - Works on any standard plate reader
- Easy results interpretation
- Cut-off, positive and negative controls included
| Application | Reactivity | Dilution info | Notes |
|---|---|---|---|
Application ELISA | Reactivity Reacts | Dilution info - | Notes - |
Select an associated product type
Human Anti-Epstein Barr virus IgG ELISA Kit (EBV-VCA) is an indirect ELISA for the qualitative detection of IgG class antibodies against Epstein Barr virus (EBV-VCA) in human plasma and serum samples.
- Colorimetric readout - 450 nm - Works on any standard plate reader
- Easy results interpretation
- Cut-off, positive and negative controls included
| Sample | n | C.V. |
|---|---|---|
Sample Serum | n 10 | C.V. 2.9 |
| Sample | n | C.V. |
|---|---|---|
Sample Serum | n 15 | C.V. 4.3 |
Abcam’s anti-Epstein Barr virus (EBV-VCA) IgG Human in vitro ELISA (Enzyme-Linked Immunosorbent Assay) kit is designed for the accurate qualitative measurement of IgG class antibodies against Epstein Barr virus Viral capsid antigen (VCA) in Human serum and plasma.
A 96-well plate has been precoated with Epstein Barr virus antigens to bind cognate antibodies. Controls or test samples are added to the wells and incubated. Following washing, a horseradish peroxidase (HRP) labelled anti-Human IgG conjugate is added to the wells, which binds to the immobilized Epstein Barr virus-specific antibodies. TMB is then catalyzed by the HRP to produce a blue color product that changes to yellow after adding an acidic stop solution. The density of yellow coloration is directly proportional to the amount of Epstein Barr virus IgG sample captured in plate.
Epstein-Barr Virus (EBV) VCA IgG antibodies are molecular indicators developed by the immune system in response to the structural proteins of the viral capsid of EBV particularly the viral capsid antigen (VCA). These proteins facilitate the formation of the viral shell. VCA IgG antibodies typically have a mass of approximately 150 kDa and are expressed during the acute and convalescent phases of EBV infection. The presence of these antibodies can often be found in serum samples indicating past infection since VCA IgG appears late and persists for a lifetime.
EBV VCA IgG antibodies participate in the immune surveillance mechanism against the EBV. They belong to the immunoglobulin class and indicate an adaptive immune response helping to neutralize viral particles and prevent EBV from causing further infection. These antibodies do not work as part of a larger complex but operate independently to tag viral particles for destruction by immune cells. The detection of these antibodies therefore serves as a marker for prior EBV exposure and helps assess the immune status of individuals.
EBV VCA IgG antibodies primarily influence immune response pathways particularly the humoral immune response. They do not directly participate in signaling pathways but result from the activity of B cells within the adaptive immune system as they recognize EBV VCA. B cell differentiation and activation are closely related and proteins like CD20 and CD19 are important in this process as they support the proliferation and development of antibody-producing cells.
EBV VCA IgG antibodies relate directly to infectious mononucleosis a condition commonly caused by EBV. A high level of these antibodies indicates a past or ongoing EBV infection and can aid in the diagnosis of mononucleosis. Furthermore chronic active EBV infection can be represented by persistent high titer levels of EBV VCA IgG. It is essential to acknowledge the connection of these antibodies to EBV-associated cancers such as Burkitt's lymphoma where EBV contributes to the oncogenic process along with other proteins like LMP1 (latent membrane protein 1) which play significant roles in tumorigenesis.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com